Lori Ehrlich, MD, PhD
CHOP Hematology/Oncology Fellow
M.D./Ph.D. from University of Pittsburgh. Lori’s research project involves elucidating the precise molecular mechanisms by which the Ataxia Telangiectasia Mutated, BCL11B, and TRP53 tumor suppressor proteins interact to coordinate the cellular DNA damage response, preventing genomic instability and the development of leukemia and lymphoma. The ultimate goal is to use this knowledge to develop patient-specific cancer therapies that exploit the aberrant DNA damage responses intrinsic to tumor cells.